Bifidobacterium infantis is a commercially available probiotic, isolated from infant feces, and hypothesized to grow on 2'-FL because of subspecies identity.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT | Size | Price | Quantity | |
---|---|---|---|---|
LBGF-0722-GF56 |
|
Product Information | |
---|---|
Product Overview | Bifidobacterium infantis is a commercially available probiotic, isolated from infant feces, and hypothesized to grow on 2'-FL because of subspecies identity. |
Target | Bifidobacterium |
Genus | Bifidobacterium |
Application | Study and research |
Culture Medium | BBL |
Culture Conditions | 37°C; Anaerobic |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Bifidobacterium is Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They are originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS. |
Alternative Names | Bifidobacterium infantis |
Bifidobacterium infantis is primarily utilized for its ability to metabolize human milk oligosaccharides (HMOs), aiding in the study of gut microbiota development and its impact on health. This strain is particularly valuable in understanding the gut-brain axis and its implications for cognitive and structural brain development.
Bifidobacterium infantis should be cultured in an anaerobic medium that supports the growth of bifidobacteria, such as MRS broth supplemented with cysteine hydrochloride. The addition of specific prebiotics like 2'-fucosyllactose (2'-FL) can further enhance its growth.
Under optimal conditions, Bifidobacterium infantis typically reaches log phase growth within 18-24 hours. Monitoring the growth curve is essential to determine the appropriate time for harvesting cells for downstream applications.
To prepare Bifidobacterium infantis for in vivo studies, the culture should be grown to the desired phase, harvested by centrifugation, and resuspended in a suitable carrier (e.g., glycerol or PBS). This preparation can then be administered to the experimental subjects, ensuring accurate dosing and consistency.
The viability of Bifidobacterium infantis can be assessed using colony-forming unit (CFU) counts on selective agar plates. Viable counts should be performed immediately before use to ensure the probiotic's effectiveness in experiments.
Total body weight gain of piglet
The research investigated the impact of formula supplementation with 2'-fucosyllactose (2'-FL) and Bifidobacterium longum subsp.infantis Bi-26 (Bi-26) on piglet growth, organ weights, and intestinal development. Utilizing a 2×2 design, two-day-old piglets were randomized to receive either a control diet or a diet supplemented with 1.0 g/L 2'-FL, with further sub-groups receiving either Bi-26 or no probiotic. Over the study period, body weights and food intake were monitored, with no significant differences in formula intake among groups. The study found that piglets fed with 2'-FL or Bi-26 showed a significant reduction in ileal crypt depth, suggesting a potential for decreased intestinal cell proliferation. However, overall growth and organ development were unaffected by the treatments, indicating that supplementation did not adversely affect the animals. The addition of 2'-FL increased sucrase activity in the ileum, highlighting a possible enhancement in digestive function. These findings suggest that 2'-FL and Bi-26 can support piglet growth and intestinal development without negative impacts, potentially offering benefits for formula-fed infants.
Daniels, V. C., Monaco, M. H., et al. Evaluation of 2'-fucosyllactose and Bifidobacterium longum subspecies infantis on growth, organ weights, and intestinal development of piglets. Nutrients. 2021, 14(1): 199. Distributed under Open Access license CC BY 4.0, without modification.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.